Clinical Trials Browser

Phase 2 × pralsetinib × 90 days × Clear all

NCT04302025 2026-05-22

NAUTIKA1

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Active not recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT06563999 2026-04-21

NUMER

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms